Zoxamide Metabolite 1
APC-1650
Zoxamide Metabolite 1
Cat. No.
APC-1650
CAS No.
209809-69-8
MF
C14H17Cl2NO2
MW
302.2
Zoxamide Metabolite 1 is a monodechlorinated Zoxamide metabolite.
Technical Service Need help? Our team of experienced experts is here for you with full support.
86-28-85159085 
info@aktin.com Technical Data
Description
Storage and Shipping
References
Product Name
CAS No.
209809-69-8
MF
C14H17Cl2NO2
MW
302.2
Specification
95%
Research Area
Analytical reference material
Description
Zoxamide Metabolite 1 is a monodechlorinated Zoxamide metabolite. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g Availability: In stock
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Oesch F, et al. In vitro mammalian metabolism of the mitosis inhibitor zoxamide and the relationship to its in vitro toxicity. Xenobiotica. 2010;40(1):72-82.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
APC-1809
(-)-Curine
CAS No.:436-05-5
MF:C36H38N2O6
APC-1808
Fusicoccin from Fusicoccum amygdali
CAS No.:20108-30-9
MF:C36H56O12
APC-1806
Albine formate
CAS No.:53915-26-7(free base)
MF:C15H22N2O3
APC-1805
OSW-1
CAS No.:145075-81-6
MF:C47H68O15
APC-1804
Angustifoline formate
CAS No.:550-43-6（free base）
MF:C15H24N2O3
APC-1803
Aloe-emodin 8-O-β-D-(6'-galloyl)glucopyranoside
CAS No.:1374014-36-4
MF:C28H24O14
APC-1800
(+)-allo-Hydroxycitric acid calcium salt /Hibiscus acid calcium
CAS No.:27750-11-4 (free base)
MF: C12H10Ca3O16
APC-1799
Isoengeletin
CAS No.:30987-58-7
MF:C21H22O10
APC-1798
Isoastilbin
CAS No.:54081-48-0
MF:C21H22O11
APC-1797
(-)-3-Dehydroshikimic acid
CAS No.:2922-42-1
MF:C7H8O5
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
